Glucocorticoid Receptor 

 186 Products   186 Products   1696 Diseases   95004 News 


«12...370371372373374375376377378379380...10671068»
  • ||||||||||  dexamethasone / Generic mfg.
    Journal:  Anti-inflammatory action of betulin and its potential as a dissociated glucocorticoid receptor modulator. (Pubmed Central) -  Feb 10, 2022   
    This work aims to confirm the hypothesis that betulin has dexamethasone-like anti-inflammatory action through glucocorticoid receptor (GR)-mediated pathway...Both of the hydrophobic and hydrogen-bonding interactions stabilized the binding between betulin and GR during the simulation process. In conclusion, betulin might be a potential dissociated GR modulator with a reduced side effect profile yet keeping its anti-inflammatory action.
  • ||||||||||  Opdivo (nivolumab) / Ono Pharma, BMS
    Clinical, Journal, Adverse events, Checkpoint inhibition:  Side effects of immune-checkpoint inhibitors: Can multiple side effects be seen in a patient? (Pubmed Central) -  Feb 10, 2022   
    In conclusion, betulin might be a potential dissociated GR modulator with a reduced side effect profile yet keeping its anti-inflammatory action. This case emphasizes the need for patient's education and awareness of immune-related adverse events, and the importance of understanding the management of life-threatening complications of the checkpoint inhibitors, because these side effects require prompt recognition and treatment.
  • ||||||||||  Dulera (mometasone/formoterol) / Merck (MSD), Novartis
    Review, Journal:  A Practical Guide to Implementing SMART in asthma management. (Pubmed Central) -  Feb 10, 2022   
    The SMART regimen should be introduced with a careful explanation of its role in self-management and preferably with a customized written asthma action plan. The cost to patients and availability of SMART treatment will depend on prescribed dose and national/local payer agreements.
  • ||||||||||  Sutent (sunitinib) / Pfizer
    Clinical, Journal:  Sunitinib induced colitis manifesting as invasive diarrhea in a patient with renal cell carcinoma. (Pubmed Central) -  Feb 10, 2022   
    Diarrhea is a frequent symptom in patients treated with tyrosine kinase inhibitors, however the described pathologic findings have rarely been reported. Our aim is to emphasize the importance of close follow-up in patients treated with tyrosine kinase inhibitors, and to raise awareness on the management of sunitinib induced colitis.
  • ||||||||||  dexamethasone / Generic mfg.
    Observational data, Journal:  Three waves of COVID-19 in a Norwegian local hospital. (Pubmed Central) -  Feb 9, 2022   
    Differences in patient characteristics and changes to treatment methods, such as the use of dexamethasone and non-invasive ventilation support, may have contributed to the apparent fall in mortality from the first to the third wave. Conditions that are not registered in the study, such as vaccination status, may also have impacted on mortality.
  • ||||||||||  Darzalex (daratumumab) / J&J
    Enrollment closed, Trial completion date, Trial primary completion date:  ASCENT: Aggressive Smoldering Curative Approach Evaluating Novel Therapies and Transplant (clinicaltrials.gov) -  Feb 9, 2022   
    P2,  N=87, Active, not recruiting, 
    Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | Trial completion date: Jun 2026 --> Jan 2034 | Trial primary completion date: Jun 2022 --> Jan 2024
  • ||||||||||  Olumiant (baricitinib) / Incyte, Eli Lilly
    Enrollment change:  Adaptive COVID-19 Treatment Trial 4 (ACTT-4) (clinicaltrials.gov) -  Feb 9, 2022   
    P3,  N=1010, Completed, 
    Recruiting --> Active, not recruiting | Trial completion date: Jun 2026 --> Jan 2034 | Trial primary completion date: Jun 2022 --> Jan 2024 N=4074 --> 1010
  • ||||||||||  Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
    Clinical, Journal:  Stain Associated Autoimmune Myopathy: Case Report With Delayed Onset and Treatment Challenges. (Pubmed Central) -  Feb 8, 2022   
    Symptoms began when restarting atorvastatin 40 mg daily for a recent NSTEMI, following 10 years of statin use, interrupted after diagnosis of NASH...Newly diagnosed with SAAM, symptoms improved with methylprednisolone and intravenous immunoglobulin (IVIG), continuing outpatient as daily prednisone and monthly IVIG...Clinical findings and positive anti-HMGCR antibodies confirmed the diagnosis. Recurrent relapses required triple combination therapy including addition of rituximab to achieve remission.
  • ||||||||||  Actemra IV (tocilizumab) / Roche, JW Pharma
    Clinical, Journal:  Pragmatic Recommendations for Therapeutics of Hospitalized COVID-19 Patients in Low- and Middle-Income Countries. (Pubmed Central) -  Feb 8, 2022   
    We recommend against using hydroxychloroquine ± azithromycin or lopinavir-ritonavir...We recommend using oral or intravenous low-dose dexamethasone in adults with COVID-19 disease who require oxygen or mechanical ventilation...We also recommend using low-dose corticosteroids in patients with refractory shock requiring vasopressor support. We recommend against the use of convalescent plasma and interleukin-6 inhibitors, such as tocilizumab, for the treatment of COVID-19 in LMICs outside of clinical trials.
  • ||||||||||  budesonide / Generic mfg., cyclosporine / Generic mfg.
    Review, Journal:  A reasoned approach to the treatment of autoimmune hepatitis. (Pubmed Central) -  Feb 8, 2022   
    Alternative first-line treatment with budesonide is effective in adults, but less so in the juvenile form of AIH; first-line treatment with ciclosporin does not provide convincing advantages compared to standard treatment...Mycophenolate mofetil is the most widely used second-line drug, and has good efficacy particularly for patients intolerant to azathioprine, but is teratogenic...Biologicals, including anti-tumour necrosis factor- α and anti-CD20 monoclonal antibodies, have given ambivalent results and may have severe side-effects. Clinical trials with new therapeutic options aiming at targeting B lymphocytes and proinflammatory cytokines, or expanding regulatory T cells to restore tolerance are ongoing.
  • ||||||||||  dexamethasone / Generic mfg.
    Journal:  The STING-IRF3 pathway contributes to paraquat-induced acute lung injury. (Pubmed Central) -  Feb 8, 2022   
    The above changes were all attenuated by dexamethasone treatment (5 mg/kg, i.p., qd)...Sting silencing also inhibited the protein and mRNA levels of IRF3 in vitro. Our study suggests that STING-IRF3 signaling contributes to PQ-induced ALI, providing new information for future treatment strategies.
  • ||||||||||  fluticasone propionate/salmeterol xinafoate inhalation powder / Generic mfg.
    Clinical, Journal, Real-world evidence:  Comparing initial LABA-ICS inhalers in COPD: Real-world effectiveness and safety. (Pubmed Central) -  Feb 8, 2022   
    In a real-world clinical setting of COPD treatment, a budesonide-formoterol inhaler was generally as effective at reducing the incidence of moderate-severe exacerbations as fluticasone-salmeterol. However, budesonide-formoterol was more effective than fluticasone-salmeterol at reducing the incidence of severe exacerbation and the risk of severe pneumonia, particularly in patients with higher blood eosinophil counts.
  • ||||||||||  dexamethasone / Generic mfg.
    Preclinical, Journal:  Glucocorticoid Regulates the Synthesis of Porcine Muscle Protein through mA Modified Amino Acid Transporter SLC7A7. (Pubmed Central) -  Feb 8, 2022   
    We prove that dexamethasone affects the expression of SLC7A7, a main amino acid transporter for protein synthesis by affecting the level of mA modification in PSCs. In addition, we find that SLC7A7 affects the level of PSC protein synthesis by regulating the conduction of the mTOR signaling pathway, which indicates that the reduction of SLC7A7 expression may alleviate the level of protein synthesis under stress conditions.